Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101612 | 0.93 | KDM4E (0.33) | ESR1HDAC3MEN1KMT2ARAB9A | |
| SCHEMBL22101822 | 0.89 | ESR1 (0.31) | ESR1 | |
| SCHEMBL22101651 | 0.89 | NPC1 (0.38) | MEN1KMT2ALMNAMAPTRAB9A | |
| SCHEMBL22101657 | 0.88 | HSD11B1 (0.41) | MEN1KMT2AMAPTRAB9A | |
| SCHEMBL22101639 | 0.88 | ITGA1 (0.32) | ESR1 | |
| SCHEMBL22101959 | 0.88 | NPC1 (0.35) | MEN1KMT2AMAPTRAB9A | |
| SCHEMBL22102004 | 0.88 | SMN1; SMN2 (0.40) | CES2MEN1KMT2ALMNAMAPT | |
| SCHEMBL22101675 | 0.88 | MEN1 (0.32) | ESR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL22101679 | 0.88 | DAO (0.38) | CES2LMNA | |
| SCHEMBL22101656 | 0.88 | LMNA (0.43) | CES2MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | ESR1 1937/4885CES2 701/4885ESR2 2842/4885 |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | ESR1 1937/4885CES2 701/4885ESR2 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.